Novoxel Inc. and GPOphtho have announced a strategic partnership to expand access to innovative dry eye treatments across the United States, with the collaboration focusing on delivering the FDA-cleared Tixel device family to ophthalmologists and optometrists nationwide. The agreement grants GPOphtho's network discounted pricing and value-added packages for Novoxel's Tixel devices, addressing the growing need for effective dry eye therapies.
Breakthrough Technology for Meibomian Gland Dysfunction
The centerpiece of this partnership is the Tixel i device, specifically designed to treat Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease. According to a recent clinical trial conducted by Sanni et al. in 2025, Tixel i has been validated as a safe, non-pharmacologic, first-line treatment for MGD.
"What sets Tixel i apart from other dry eye treatments is that it only takes 2 minutes for both eyes to be treated. Unlike older technology, Tixel i safely treats upper and lower eyelids to maximize improvement," explains Cynthia Matossian, MD, FACS, and CEO of GPOphtho.
The device utilizes Novoxel's proprietary Thermo-Mechanical Action (TMA) technology to deliver clinical results through non-invasive treatments. The FDA-cleared family of products offers several advantages including no needles, bleeding, or pain, minimal downtime, no expensive consumables, and radiation-free operation that eliminates the need for safety eyewear for clinicians.
Expanding Practice Capabilities for Eyecare Professionals
The partnership addresses a significant opportunity for eyecare physicians to diversify their practice offerings. "Eyecare physicians are uniquely positioned to incorporate aesthetic procedures into their practices due to their expertise in the periocular anatomy and their familiarity with ophthalmic laser technology," notes Dr. Matossian.
The Tixel device family provides year-round treatments suitable for all skin types and age groups, enabling eyecare professionals to integrate both functional dry eye treatments and cosmetic procedures. This dual capability creates new revenue streams while enhancing patient satisfaction through comprehensive care options.
Technology and Clinical Innovation
Established in 2011, Novoxel Ltd. has focused on scientific and clinical innovation, securing numerous patents worldwide for its Tixel technology. The company's approach centers on delivering noticeable clinical results through non-invasive treatments that minimize patient discomfort and operational complexity for healthcare providers.
The absence of expensive single-use cartridges and the radiation-free nature of the treatments make the technology both cost-effective and safe for routine clinical use. These features address common barriers to adoption of new medical devices in ophthalmology practices.
Market Access and Implementation
GPOphtho, functioning as a comprehensive ophthalmic group purchasing organization, leverages collective buying power to negotiate favorable terms for its members. The organization's mission focuses on saving members time and money while allowing physicians to concentrate on patient care.
Existing GPOphtho members can inquire about adding Tixel devices through their established contacts, while new eyecare physicians can join GPOphtho at no cost to access the negotiated pricing packages. The partnership represents a commitment from both organizations to bring cutting-edge technology to more patients and practices across the United States.
